Morphologic Correlations with Homologous Recombination Deficiency in BRCA1/2-Mutated and Non-BRCA-Mutated High-Grade Serous Carcinomas

被引：0
|
作者：
Chapagain, Udita [1 ]
Sun, Lulu [2 ]
机构：
[1] Washington Univ St Louis, St Louis, MO USA
[2] Washington Univ, Sch Med, St Louis, MO USA
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
895
引用
收藏
页码：S1121 / S1122
页数：2
相关论文
共 50 条
  • [31] PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
    G E Konecny
    R S Kristeleit
    British Journal of Cancer, 2016, 115 : 1157 - 1173
  • [32] The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer
    Meisel, J. L.
    Hyman, D. M.
    Garg, K.
    Zhou, Q.
    Dao, F.
    Bisogna, M.
    Gao, J.
    Schultz, N. D.
    Grisham, R. N.
    Phillips, M.
    Iasonos, A.
    Kauff, N. D.
    Levine, D. A.
    Soslow, R. A.
    Spriggs, D. R.
    ANNALS OF ONCOLOGY, 2014, 25 (12) : 2372 - +
  • [33] BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer
    Royfman, Rachel
    Whiteley, Emma
    Noe, Olivia
    Morand, Susan
    Creeden, Justin
    Stanbery, Laura
    Hamouda, Danae
    Nemunaitis, John
    FUTURE ONCOLOGY, 2021, 17 (21) : 2817 - 2830
  • [34] PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
    Konecny, G. E.
    Kristeleit, R. S.
    BRITISH JOURNAL OF CANCER, 2016, 115 (10) : 1157 - 1173
  • [35] Reversing platinum resistance in high-grade serous ovarian carcinoma: targeting BRCA and the homologous recombination system
    Wiedemeyer, W. Ruprecht
    Beach, Jessica A.
    Karlan, Beth Y.
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [36] Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2
    Clarfield, Lauren
    Diamond, Laura
    Jacobson, Michelle
    CURRENT ONCOLOGY, 2022, 29 (03) : 2132 - 2140
  • [37] Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers
    Reitsma, Welmoed
    Mourits, Marian J. E.
    de Bock, Geertruida H.
    Hollema, Harry
    MODERN PATHOLOGY, 2013, 26 (04) : 572 - 578
  • [38] Spatially resolved molecular features in the tumor-immune microenvironment of germline BRCA1/2 mutated versus BRCA wild type high grade serous ovarian cancers
    Qian, Jing
    Roman, Lynda D.
    Bassiouni, Rania
    Rajpara, Seeta
    Neuman, Monica
    Khetan, Varun
    Craig, David W.
    Carlson, Joseph W.
    Carpten, John D.
    CANCER RESEARCH, 2024, 84 (06)
  • [39] Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers
    Wineland, Dylane
    Le, Anh N.
    Hausler, Ryan
    Kelly, Gregory
    Barrett, Emanuel
    Desai, Heena
    Wubbenhorst, Bradley
    Pluta, John
    Bastian, Paul
    Symecko, Heather
    D'Andrea, Kurt
    Doucette, Abigail
    Gabriel, Peter
    Reiss, Kim A.
    Nayak, Anupma
    Feldman, Michael
    Domchek, Susan M.
    Nathanson, Katherine L.
    Maxwell, Kara N.
    JCO PRECISION ONCOLOGY, 2023, 7
  • [40] Homologous Recombination Defects and Lung Carcinomas-Mutational Spectrum of ATM, BRCA1 and BRCA2-altered Lung Carcinomas
    Yoon, Ju-Yoon
    Rosenbaum, Jason
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1829 - 1830
12345